Home
About
Overview
Management Team
Board of Directors
Scientific Advisory Board
Careers
Therapeutic Areas
Fibromyalgia
Agitation in Alzheimer's Disease
Biodefense
Major Depressive Disorder
Posttraumatic Stress Disorder
Coronavirus Disease 2019 (COVID-19)
Pipeline
Overview
TNX-102 SL for Fibromyalgia
TNX-601 for Major Depressive Disorder (Depression)
TNX-801 for Biodefense
TNX-1800 (COVID-19 Vaccine)
TNX-3500 (COVID-19 Antiviral)
Scientific Presentations
Expanded Access Policy
News & Events
Press Releases
Tonix In The News
Investor Presentations
IR Events
Op-eds
Investors
Investor Relations
IR Overview
News / Press Releases
News / Press Releases
Press Releases
Tonix In The News
Email Alerts
Presentations & Events
Investor Presentations
IR Events
Multimedia
Multimedia
Financial Info
Financial Info
Balance Sheet
Income Statement
Cash Flow
Related Documents
Financial Results
SEC Filings
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Stock Info
Quote
Charts
Historical Data
Analyst Coverage
Governance
Governance
Board of Directors
Board Committees
Governance Documents
Contact
Site Info
Home
Site Info
Site Info
Terms of Use
Privacy Policy
Sitemap
Contact
Site Info
About Tonix Pharmaceuticals
Investor Relations
